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For over 10 years cardiac stem cell therapy has received a
considerable amount of attraction, potential, and research
money. Autologous bone marrow stem cell therapy has been
reported to be safe and to substantially increase cardiac func-
tion [1–4]. However, this beneficial effect is not invariably the
case as shown in 2011 by the Dutch HEBE trial directed by the
Interuniversity Cardiology Institute of the Netherlands togeth-
er with the Netherlands Heart Foundation (ICIN/NHS) [5–7].
More importantly, the present cardiac bone marrow stem cell
research trials have differed in the effect sizes they reported,
for reasons that are not fully understood. A recent meta-
analysis published in the British Medical Journal (BMJ) on
28 April 2014, the so-called DAMASCENE study [8], did
show that many of the most promising results in the field are
illusive and that the potential benefits of stem cells to treat
heart disease are probably far more modest than has been
presumed until now. By pooling all available results from
trials of bone marrow stem cells in patients with ischaemic
heart disease or congestive heart failure, a Cochrane review
found slight evidence to suggest a benefit for stem-cell therapy
in those populations. In pooled results from smaller
randomised trials it was shown that bone marrow stem cell
treatment was associated with reduced mortality (RR 0.28,
95 % CI 0.14–0.53) and less hospitalisations for heart failure
(RR 0.26, 95 % CI 0.07–0.94) at follow-up exceeding 1 year.
However, the quality of the evidence was considered low, and
no significant differences were seen in those outcomes with
shorter follow-up. Additionally, it was commented that ‘this
research raises disturbing questions about ethics and re-
search conduct and misconduct in a high-flying field’ [9].
What did the BMJ study address in depth? Nowbar from
the group of Francis (Imperial College, London, UK) investi-
gated whether discrepancies in trials of use of bone marrow
stem cells in patients with heart disease account for the vari-
ations in reported effect size in improvement of left ventricular
function [8]. To that purpose, the authors selected randomised
controlled trials that evaluated the effect of autologous bone
marrow stem cells for heart disease on mean left ventricular
ejection fraction (LVEF). The trials were examined for dis-
crepancies and categorised into the following three types: 1)
discrepancies in the design-for example, conflicting state-
ments as to whether the study was randomised; 2) discrepan-
cies in methods and baseline characteristics-for example,
sample or subgroup sizes that could not be an integer number
of patients; 3) discrepancies in results-for example, conflicts
between tables and figures or impossible values. In total, over
600 discrepancies in 133 reports from 49 trials were found.
One of the most important findings was a remarkable associ-
ation between the number of discrepancies and the reported
change in LVEF with bone marrow stem cell therapy, i.e.
between the number of errors and the treatment effect. The
five studies with no discrepancies showed no improvement in
LVEF (−0.4 %), whereas the five studies with the largest
number of discrepancies (>30) showed a significant improve-
ment in LVEF (+7.7 %).
The authors had no straightforward explanation for the
observed discrepancies. One possibility is that investigators
might feel pressure for results to match expectations. One
signal of a misguided desire to please is the phenomenon of
directed editing of rounded percentages to force them to add
up to 100%. In reality, correctly rounded percentages often do
not add up to 100 % when there are many categories. Second-
ly, exciting new treatments might be reported before full
checking. One signal of this, in the neighbouring speciality
of cardiomyocyte-derived stem cell therapy, is the insertion of
the word ‘randomised’ into the title of the journal publication
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that was not present in the manuscript. There were seven
controls in total, but after subtraction of the four who were
not randomised and one whowas randomised to stem cells but
refused treatment, the number of randomised controls was
only two. Thirdly, bone marrow stem cell therapy might be
less effective when it is carried out in a rigidly standardised
way. Institutions with less attention to detail might incorporate
an unnoticed contaminant that enhances the effect of treat-
ment, producing reports with more discrepancies. The final
possibility is that in the reports with the fewest discrepancies,
the LVEF effect might also have been measured with least
error. If so, the true effect of bone marrow stem cells on
ejection fraction is zero.
What lessons can be learned from this meta-analysis. The
authors strongly suggest that the following useful information
can be drawn for the design of future trials of bone marrow
stem cells: 1) prior registration on a public clinical trial regis-
try should become universal and will be helpful in
distinguishing unambiguously between trials that were multi-
ply published or merely identical by coincidence; 2) reports
should include a spreadsheet of all the data used for construc-
tion of the tables, so that incorrect values could be more easily
identified (disclosing the individual patient data could help to
correct more errors); 3) it is important for studies, when solely
relying on changes in LVEF as an endpoint, to be properly
designed to resist error and to have adequate sample size to
‘beat’ the effects of biological variability. LVEF is a change-
able variable, which in some modalities is easily manipulated
innocently by clinicians who have prior beliefs on what a
realistic value should be for a particular patient. Sample size
planning can sometimes be erroneously omitted when clini-
cians are enthusiastic to demonstrate the effectiveness of a
treatment seen as exciting.
These astonishing findings call into question the validity of
cardiac stem cell therapy; is it as beneficial as has been
proclaimed? Recently two important papers from the stem
cell expert group led by Piero Anversa (Boston, USA), one
published in Circulation in 2012 [10] and one in the Lancet in
2011 [11], have been discredited as a result of an ongoing
investigation at Harvard Medical School and Brigham and
Women’s Hospital in Boston. As a result of this investigation,
the Circulation paper was recently (22 April 2014) retracted
by the American Heart Association because ‘the data are
sufficiently compromised that a retraction is warranted’
[10]. The Lancet, which published the SCIPIO study in 2011
(also from the Boston group) [11, 12], issued a formal
Expression of Concern in March of this year. Francis
and colleagues had already issued a warning about this
in 2013 [13], when they expressed devastating critiques
of multiple papers from the German research group
directed by Strauer [14], and the C-CURE study published
in the Journal of the American College of Cardiology (JACC)
[15].
To summarise, the current meta-analysis in BMJ clearly
shows that any reports of trials of bone marrow stem cell
therapy contain factual discrepancies. Avoiding discrepancies
is difficult but is important because discrepancy count is
related to effect size. Trials with over 30 discrepancies report
a large effect size, whereas trials with fewer discrepancies
have found progressively smaller effect sizes, culminating in
discrepancy-free trials reporting an effect size of zero. The
mechanism is still unknown but should be explored in the
design of future bone marrow stem cell trials. Consequently,
there is an obvious need for large-scale, adequately powered
studies with well-defined participant cohorts and long-term
follow-up to confirm (or refute) the beneficial effects of bone
marrow stem cells in terms of improved cardiac function, less
hospitalisations and reduced mortality.
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